Dimension Capital's $800M third fund shows the intersection of science and compute is booming

Dimension Capital, a New York venture firm founded in late 2022 to invest at the crossroads of biotech and software, has closed an $800 million third fund — a 60% jump from the $500 million second fund it raised just 18 months earlier. The size of the increase is itself a signal of how much investor appetite has grown for startups that blend advanced computing with life sciences.

Betting on the science-compute intersection

The firm was founded by Zavain Dar, Adam Goulburn, and Nan Li, three partners who previously worked together at Lux Capital and Obvious Ventures before striking out to build a fund focused specifically on deep-tech companies operating where biology and software increasingly overlap. That thesis has become considerably more mainstream since Dimension's founding, as AI-driven drug discovery, computational biology, and longevity research have all attracted a wave of new capital from generalist and specialist investors alike.

Portfolio bets that have already paid off

Dimension's existing portfolio illustrates why investors are willing to back a larger fund. Chai Discovery, an AI-driven drug development platform, was co-led by Dimension in a $30 million seed round back in 2024; the company has since raised a $400 million round at a $3.8 billion valuation as of this July, a roughly 127x jump in valuation in under two years.

New Limit, an anti-aging startup co-founded by Coinbase CEO Brian Armstrong, followed a similar trajectory. Dimension backed the company's Series A in January 2025, and New Limit completed a Series C this July at a $3.1 billion valuation. The firm also holds a stake in Modal Labs, an inference infrastructure company, and picked up shares in Anthropic indirectly after the AI lab acquired portfolio company Coefficient Bio for roughly $400 million in April.

Why the fund size matters

An 60% step-up between fund two and fund three, closed in under two years, reflects both strong returns on Dimension's earlier bets and a broader surge of capital chasing the same thesis: that the next generation of breakthrough biotech companies will be built as much on compute and machine learning as on wet-lab science. With deep-pocketed AI labs now directly acquiring biotech startups for their platforms — as Anthropic did with Coefficient Bio — venture firms positioned early at that intersection are finding themselves with an unusually direct line to some of the most valuable exits in the current market.

The larger fund gives Dimension more room to lead rounds rather than simply participate in them, and to follow on more aggressively in companies like Chai Discovery and New Limit as they scale toward late-stage rounds and eventual public offerings.

A crowded but still-growing field

Dimension is far from alone in chasing this thesis; a wave of specialist and generalist funds alike have piled into biotech-software crossover startups over the past two years as computational approaches to drug discovery, protein design, and longevity research have matured from academic curiosities into commercially fundable businesses. What differentiates Dimension's pitch to limited partners is a track record already validated by two of its highest-profile bets reaching multibillion-dollar valuations within a relatively short window, giving the firm concrete evidence, rather than just thesis-level conviction, to point to when raising an even larger third fund so soon after its second.